Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATG-037 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Antengene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (ATG-037), Intravenous (pembrolizumab)
01
Overview
ATG-037 + pembrolizumab is an investigational combination therapy for advanced and metastatic solid tumors, particularly in checkpoint inhibitor (CPI)-resistant cancers such as melanoma and non-small cell lung cancer (NSCLC). ATG-037 is an orally available, small molecule inhibitor of CD73 (ecto-5'-nucleotidase), an immune checkpoint that generates immunosuppressive adenosine in the tumor microenvironment. By blocking CD73, ATG-037 can counteract adenosine-mediated suppression of anti-tumor immune responses. Pembrolizumab is an approved monoclonal antibody that targets programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to restore antitumor immunity. The combination is currently being studied in the ongoing STAMINA-01 trial, which has shown promising preliminary efficacy, including overall response rates (ORR) of 36.4% in melanoma and 22% in NSCLC, with manageable safety profiles[2][3][9][10]. ATG-037 was developed by Antengene, and pembrolizumab by Merck & Co. (MSD).
- Other names
- ATG-037 + KEYTRUDA
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)NT5E (Cluster of Differentiation 73)
Beyond the preview
Go deeper on ATG-037 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATG-037 + pembrolizumab.